四价流感病毒亚单位疫苗 | China Drugs ListQuadrivalent influenza subunit vaccine | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 江苏中慧元通生物科技股份有限公司Jiangsu Ab&B Biotechnology Co., Ltd.
- 药品类型
- 疫苗Vaccine
- 治疗领域
- 预防与诊断Prevention & diagnosis
- 公开来源记录的适应症
- 本品用于 3 岁及以上人群;尤其推荐易感者及易发生相关并发症的人群,如儿童、老年人、体弱者、流感流行地区人员等。接种本品后,可刺激机体产生抗流感病毒的免疫力。用于预防疫苗相关型别的流感病毒引起的流行性感冒。For individuals aged 3 years or older, especially those susceptible to influenza or its complications, including children, older adults, frail individuals, and people in areas with influenza outbreaks. Vaccination stimulates immunity against influenza viruses and prevents influenza caused by the vaccine-associated viral types.
- 适应症来源与口径
- 来源日期： 2025. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。 新增适应症可能由较新的公告或申报资料支持，而非旧版完整说明书；请查看适应症来源。Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- 说明书信息局限
- 适应症已与官方公开申报资料核对。尚未取得完整原始说明书。Indications checked against an official public submission. The full original prescribing information is still unavailable.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.